Moderate to severe PPP can be effectively and safely treated with apremilast through 52 weeks, with improvement seen as early as week 2.
The Dermatology Division of the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to sonelokimab (SLK) in moderate-to-severe palmoplantar pustulosis (PPP) supported by positiv ...
The phase 2a proof-of-concept trial will recruit up to 135 adult patients with mild to severe PPP to investigate the efficacy and safety of delgocitinib cream compared to cream vehicle. Delgocitinib ...
MoonLake Immunotherapeutics has announced the initiation of new trials for sonelokimab, an investigational Nanobody® aimed at treating inflammatory diseases. The Phase 3 VELA-TEEN trial will evaluate ...
Acute Generalised Exanthematous Pustulosis (AGEP) is a rare, severe cutaneous adverse reaction that most frequently occurs in response to medications. It is characterised by a rapid onset of ...
Asianet Newsable on MSN
MLTX Stock Erases Most Of 2025 Loses As Wall Street, Retail Bets On FDA Feedback For Sonelokimab
The FDA said that the drug, which treats a chronic inflammatory skin disorder, could establish evidence without additional trials.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results